Genetic predictors for FVIII inhibitors formation in a Greek population of children with severe haemophilia A exclusively treated with recombinant concentrates

Haemophilia. 2024 May;30(3):845-847. doi: 10.1111/hae.14957. Epub 2024 Apr 10.

Authors

Aikaterini Michalopoulou¹, Athina Dettoraki¹, Zoey Kapsimali¹, Kleopatra Spanou², Emmanouil Liatsis², Marina Economou³, Niki Constantinidou², Helen Pergantou¹

Affiliations

¹ Haemophilia Centre-Haemostasis and Thrombosis Unit, Agia Sofia Children's Hospital, Athens, Greece.
² Department of Immunology-Histocompatibility, Agia Sofia Children's Hospital, Athens, Greece.
³ Haemophilia Centre, First Pediatric Department, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.

PMID: 38600799
DOI: 10.1111/hae.14957

No abstract available

Publication types

Letter

MeSH terms

Adolescent
Child
Child, Preschool
Factor VIII* / genetics
Factor VIII* / therapeutic use
Female
Greece
Hemophilia A* / drug therapy
Humans
Infant
Male
Recombinant Proteins / therapeutic use

Substances

Factor VIII
Recombinant Proteins